Buscar
Vaxcyte Inc
PCVXAñadir a la lista de seguimiento
54.260USD
+0.230+0.43%
Cierre 05/13, 16:00（ET）Cotizaciones retrasadas 15 min
7.11BCap. mercado
PérdidaP/E TTM
Más Datos de Vaxcyte Inc Compañía
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
Información de Vaxcyte Inc
Símbolo de cotizaciónPCVX
Nombre de la empresaVaxcyte Inc
Fecha de salida a bolsaJun 12, 2020
Director ejecutivoPickering (Grant E)
Número de empleados414
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 12
Dirección825 Industrial Road, Ste. 300
CiudadSAN CARLOS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94070
Teléfono16508370111
Sitio Webhttps://vaxcyte.com/
Símbolo de cotizaciónPCVX
Fecha de salida a bolsaJun 12, 2020
Director ejecutivoPickering (Grant E)
Ejecutivos de Vaxcyte Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
605.14K
-9.18%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
96.84K
+40.41%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
7.17K
-20.78%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
7.17K
-20.78%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
5.61K
-40.09%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
2.56K
-392.15%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
1.55K
-96.19%
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
Dr. Heath Lukatch, Ph.D.
Dr. Heath Lukatch, Ph.D.
Independent Director
Independent Director
--
--
Ms. Annie Drapeau
Ms. Annie Drapeau
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
605.14K
-9.18%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
96.84K
+40.41%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
7.17K
-20.78%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
7.17K
-20.78%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
5.61K
-40.09%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
2.56K
-392.15%
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 10 de may
Actualizado: dom., 10 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Janus Henderson Investors
9.27%
Fidelity Management & Research Company LLC
7.98%
T. Rowe Price Investment Management, Inc.
7.82%
RA Capital Management, LP
7.43%
BlackRock Institutional Trust Company, N.A.
6.02%
Otro
61.48%
Accionistas
Accionistas
Proporción
Janus Henderson Investors
9.27%
Fidelity Management & Research Company LLC
7.98%
T. Rowe Price Investment Management, Inc.
7.82%
RA Capital Management, LP
7.43%
BlackRock Institutional Trust Company, N.A.
6.02%
Otro
61.48%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
44.10%
Investment Advisor/Hedge Fund
31.11%
Hedge Fund
17.88%
Venture Capital
9.47%
Research Firm
1.61%
Sovereign Wealth Fund
0.85%
Individual Investor
0.55%
Bank and Trust
0.46%
Pension Fund
0.45%
Participación institucional
Actualizado: dom., 5 de abr
Actualizado: dom., 5 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
718
151.93M
105.22%
-5.25M
2025Q4
699
144.28M
102.34%
-18.23M
2025Q3
668
148.53M
114.41%
-14.14M
2025Q2
654
150.97M
116.29%
-1.23M
2025Q1
669
149.26M
115.73%
-5.52M
2024Q4
629
143.44M
111.44%
-3.61M
2024Q3
579
138.80M
114.99%
+5.28M
2024Q2
508
125.57M
113.86%
-5.08M
2024Q1
487
122.06M
113.01%
+8.05M
2023Q4
444
106.09M
111.72%
-6.02M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Janus Henderson Investors
13.39M
9.3%
+282.99K
+2.16%
Dec 31, 2025
Fidelity Management & Research Company LLC
11.52M
8%
+1.18M
+11.44%
Dec 31, 2025
T. Rowe Price Investment Management, Inc.
11.30M
7.85%
+2.98M
+35.85%
Dec 31, 2025
RA Capital Management, LP
10.72M
7.45%
-1.24M
-10.37%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
8.69M
6.04%
+295.02K
+3.52%
Dec 31, 2025
Wellington Management Company, LLP
5.97M
4.15%
+933.54K
+18.55%
Dec 31, 2025
State Street Investment Management (US)
4.98M
3.46%
+194.12K
+4.06%
Dec 31, 2025
Paradigm BioCapital Advisors LP
4.07M
2.83%
+283.26K
+7.48%
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Harbor Health Care ETF
4.32%
ALPS Medical Breakthroughs ETF
2.39%
State Street SPDR S&P Biotech ETF
1.65%
Direxion Daily S&P Biotech Bull 3X Shares
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
ProShares Ultra Nasdaq Biotechnology
0.58%
Invesco Nasdaq Biotechnology ETF
0.57%
iShares Biotechnology ETF
0.5%
JPMorgan Fundamental Data Science Small Core ETF
0.44%
iShares Russell 2000 Value ETF
0.34%
Ver más
Harbor Health Care ETF
Proporción4.32%
ALPS Medical Breakthroughs ETF
Proporción2.39%
State Street SPDR S&P Biotech ETF
Proporción1.65%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción1.02%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.89%
ProShares Ultra Nasdaq Biotechnology
Proporción0.58%
Invesco Nasdaq Biotechnology ETF
Proporción0.57%
iShares Biotechnology ETF
Proporción0.5%
JPMorgan Fundamental Data Science Small Core ETF
Proporción0.44%
iShares Russell 2000 Value ETF
Proporción0.34%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
